APOC1 and hepatocellular carcinoma: Research by Hao et al. (2022) found inhibiting APOC1 promotes the conversion of M2 macrophages to M1 macrophages through the ferroptosis pathway, reshaping the tumor immune microenvironment and enhancing the response of hepatocellular carcinoma (HCC) to PD1 immunotherapy.